.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
US Army
Boehringer Ingelheim
Novartis
Colorcon
Chinese Patent Office
Fuji
Baxter
Merck

Generated: December 18, 2017

DrugPatentWatch Database Preview

VISTOGARD Drug Profile

« Back to Dashboard

Which patents cover Vistogard, and what generic alternatives are available?

Vistogard is a drug marketed by Wellstat Therap and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries and two supplementary protection certificates in two countries.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Summary for VISTOGARD

Drug patent expirations by year for VISTOGARD

Pharmacology for VISTOGARD

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wellstat TherapVISTOGARDuridine triacetateGRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Wellstat TherapVISTOGARDuridine triacetateGRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat TherapVISTOGARDuridine triacetateGRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat TherapVISTOGARDuridine triacetateGRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat TherapVISTOGARDuridine triacetateGRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat TherapVISTOGARDuridine triacetateGRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VISTOGARD

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,765Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
6,060,459 Enhancing blood cell count with oxypurine nucleosides► Subscribe
6,329,350 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
7,105,498Acylated uridine and cytidine and uses thereof► Subscribe
7,173,017Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
6,297,222 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
5,736,531 Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides► Subscribe
6,054,441 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis► Subscribe
5,246,708 Methods for promoting wound healing with deoxyribonucleosides► Subscribe
6,348,451 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VISTOGARD

Country Document Number Estimated Expiration
Canada2223640► Subscribe
Finland97891► Subscribe
Canada2150940► Subscribe
Hong Kong1004854► Subscribe
Portugal679160► Subscribe
Japan2764014► Subscribe
Australia610315► Subscribe
Japan2006096772► Subscribe
Australia621368► Subscribe
Germany3883374► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VISTOGARD

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00036Denmark► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427
0889Netherlands► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACIL OF EEN ZOUT VAN TIPIRACIL, ZOALS TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
Express Scripts
Novartis
Merck
Cipla
Fish and Richardson
Federal Trade Commission
US Department of Justice
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot